MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $31.87 | Prev. Close $32.21 | Circuit Range N/A |
Day Range $31.23 - $32.44 | Year Range $4.81 - $35.18 | Volume 6,156 |
Average Traded $32.02 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
24-Dec-25 | $31.87 | $32.13 | +0.00% |
24-Dec-25 | $31.87 | $32.13 | -0.14% |
23-Dec-25 | $33.90 | $32.17 | -7.48% |
22-Dec-25 | $30.75 | $34.77 | +14.32% |
19-Dec-25 | $28.95 | $30.41 | +6.09% |
18-Dec-25 | $27.98 | $28.67 | +3.58% |
17-Dec-25 | $28.00 | $27.68 | -0.14% |